Impact of IRA on R&D Could Result in Fewer Small Molecule Drugs, Study Says

The price reduction measures in the Inflation Reduction Act (IRA) could result in 79 fewer small molecule drugs or 188 fewer indications and 116 million life years lost over the next 20 years, a study funded by Gilead Sciences revealed.
Source: Drug Industry Daily